BTIG Maintains Buy on GeneDx Hldgs, Raises Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Mark Massaro maintains a Buy rating on GeneDx Holdings (NASDAQ:WGS) and raises the price target from $11 to $15, indicating a positive outlook on the company's stock.
April 22, 2024 | 5:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GeneDx Holdings' stock rating was maintained as Buy by BTIG analyst Mark Massaro, with the price target increased from $11 to $15.
The increase in price target by a reputable analyst suggests a strong confidence in GeneDx Holdings' future performance, likely leading to positive investor sentiment and potential short-term price increase.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100